These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2405920)

  • 61. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Gyllenhammar H; Johansson B; Juliusson G; Järnmark M
    Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Beta 2-microglobulin predicts survival in primary systemic amyloidosis.
    Gertz MA; Kyle RA; Greipp PR; Katzmann JA; O'Fallon WM
    Am J Med; 1990 Nov; 89(5):609-14. PubMed ID: 2239980
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
    Fleury J; Tortochaux J; Legros M; Cure H; Kwiatkowski F; Ferrière JP; Travade P; Dionet C; Gaillard G; Chassagne J
    Bull Cancer; 1994 Jul; 81(7):625-31. PubMed ID: 7742606
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum syndecan-1: a new independent prognostic marker in multiple myeloma.
    Seidel C; Sundan A; Hjorth M; Turesson I; Dahl IM; Abildgaard N; Waage A; Borset M
    Blood; 2000 Jan; 95(2):388-92. PubMed ID: 10627439
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
    Aref S; Goda T; El-Sherbiny M
    Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Biochemical and immunological findings of multiple myeloma].
    Asaoku H
    Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic factors and staging systems for multiple myeloma: comparisons between the Medical Research Council studies in the United Kingdom and the Southwest Oncology Group studies in the United States.
    Kelly KA; Durie B; Maclennan IC
    Hematol Oncol; 1988; 6(2):131-40. PubMed ID: 3292370
    [No Abstract]   [Full Text] [Related]  

  • 71. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
    Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
    Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma.
    Baz R; Walker E; Choueiri TK; Abou Jawde R; Brand C; McGowan B; Yiannaki E; Andresen S; Hussein MA
    Acta Haematol; 2007; 117(3):162-7. PubMed ID: 17148935
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma.
    Avilés A; Zepeda G; Díaz-Maqueo JC; Rodriguez L; Guzmán R; García EL; Talavera A
    Leuk Lymphoma; 1992 May; 7(1-2):135-8. PubMed ID: 1472924
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Merlini, Waldenström, Jayakar staging system revisited.
    Merlini G; Gobbi PG; Ascari E
    Eur J Haematol Suppl; 1989; 51():105-10. PubMed ID: 2697581
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Classification, staging and prognostic indices for multiple myeloma].
    Hotta T
    Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Prognostic significance of beta-2-microglobulin in multiple myeloma].
    Podol'tseva EI; Morozova EV; Almazov VA
    Vopr Onkol; 1996; 42(4):32-5. PubMed ID: 8928455
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Serum ferritin and beta-2-microglobulin in multiple myeloma].
    Linkesch W; Ludwig H
    Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status.
    Bataille R; Magub M; Grenier J; Donnadio D; Sany J
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):59-66. PubMed ID: 6177535
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma.
    Litam P; Swan F; Cabanillas F; Tucker SL; McLaughlin P; Hagemeister FB; Rodriguez MA; Velasquez WS
    Ann Intern Med; 1991 May; 114(10):855-60. PubMed ID: 2014946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.